Why did Moleculin Biotech Inc (NASDAQ:MBRX) Have a Rough Week?

Moleculin Biotech Inc (NASDAQ:MBRX)

Moleculin Biotech Inc (NASDAQ:MBRX) stock fell through mild support at $2.50 to close the trading week at $2.39 on light volume. The biotechnology company spent early August trying to establish a price above $3.00 but failed to do so and slid down to establish a new low for August.

Moleculin Biotech Inc (NASDAQ:MBRX)
One month stock price chart for MBRX

Moleculin Biotech Inc. (NASDAQ:MBRX) is a pre-clinical pharmaceutical company with ties to The University of Texas System on behalf of M.D. Anderson Cancer Center. Moleculin Biotech Inc. (NASDAQ:MBRX) developed Annamycin for the treatment of acute myeloid leukemia (AML). AML is the most common type of leukemia in adults. Current treatment includes combining two chemotherapeutic drugs – a treatment regime that has not substantially changed since the 1970s. Annamyecin is a unique liposome formulated anthracycline designed to limit, or erase any cardiotoxicity during treatment. This approach is taken so as to avoid the multi-drug resistance mechanism that frequently defeat the effectiveness of current drugs.

Last Monday, August 14, 2017, Moleculin Biotech Inc (NASDAQ:MBRX) released their Q2 2017 financial results. The biotech company had a Q2 net loss of $2.3 million, which included non-cash income of $1.2 million related to some warrants expiring without being exercised. The market reacted to the news by selling MBRX shares off and they closed the day down over 6%.

Then on Wednesday, Moleculin Biotech Inc (NASDAQ:MBRX) announced it acquired the WP1122 active drug compound from the company’s sub-license partner in Poland. Moleculin Biotech plans to study the drug as a potential treatment for brain tumors.

Walter Klemp, CEO of Moleculin Biotech Inc (NASDAQ:MBRX), commented “Access to this product allows us to accelerate preclinical toxicology and analytical testing of WP1122, which enables preparation of an Investigational New Drug application so we can begin proof of concept clinical trials. Research at MD Anderson using live human brain tumors transplanted into mice has shown that WP1122 has the potential to outperform the current standard of care treatment for glioblastoma, one of the most pervasive forms of brain tumors.”

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Moleculin Biotech Inc (NASDAQ:MBRX) Spikes On MD Anderson Cooper Center Technology Licensing Agreement

Moleculin Biotech Inc (NASDAQ:MBRX)

Moleculin Biotech Inc (NASDAQ:MBRX) traded higher in Tuesday’s trading session after announcing the signing of a new technology license agreement with MD Anderson Copper Center for the Leukemia drug Annamycin. The stock was up by 20.59% to end the day at $2.05 a share. The rally also comes after the company regained compliance with the NASDAQ Listing Requirements.

Moleculin Biotech Inc (NASDAQ:MBRX)
Bar Graph $MBRX

Technology License Agreement

Moleculin Biotech Inc (NASDAQ:MBRX) is a preclinical stage pharmaceutical company specializing in the development of anti-cancer drugs. Annamycin is the company’s lead drug candidate for the treatment of refractory acute myeloid leukemia. The company is also working on two other molecular portfolios, one of which is working on the modulation of hard-to-target tumor cell signaling mechanisms. The other molecule targets the metabolism of tumors.

The technology license agreement with MD Anderson’s Cooper Cancer Center is based on new patent applications that Moleculin is set to file. The patents are in relation to the company’s candidate drug Annamycin.

“In anticipation of beginning our planned clinical trials for Annamycin. One of our priorities has been to ensure the best possible protection for our intellectual property. Some key patent applications had yet to be filed and signing a new license agreement with MD Anderson clears the way for those patents,” said Walter Klemp, Moleculin Biotech Inc (NASDAQ:MBRX) CEO.

Dr. Gill Appointment

Moleculin Biotech Inc (NASDAQ:MBRX) has already appointed Dr. Lidia Gil of Poznan University to act as the lead European Principal Investigator. Dr. Gil is to oversee the planned Phase I/II clinical trial for Annamycin for the treatment of acute myeloid leukemia. The company has also expanded its engagement with CRO to include clinical sites in Poland.

Mayo Clinic WP1066 Partnership

Separately, Moleculin Biotech Inc (NASDAQ:MBRX) has entered into an agreement with Physicians at the Mayo Clinic as part of an effort that seeks to enable additional research on WP1066 molecule as a possible treatment for a rare form of pediatric tumors.

Under the terms of the agreement, the company is to supply Mayo Clinic physicians and scientists with WP1066 for preclinical testing as a novel treatment for Pediatric Diffuse Intrinsic Pontine Gliomas. The primary target with the upcoming trials is cell signaling protein STAT3. Initial studies have shown that WP1066 has the potential to suppress xenograft of human brain tumors transplanted into mice

“This, along with the physician efforts at MD Anderson to secure an IND to study WP1066 for the treatment of adult brain tumors, continues to validate the potential importance of WP1066 in the treatment of difficult tumors,” said Mr. Klemp.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Moleculin Biotech Inc (NASDAQ:MBRX) Announces Scientific Support For Research Endeavor At Mayo Clinic

Moleculin Biotech Inc (NASDAQ:MBRX)

Moleculin Biotech Inc (NASDAQ:MBRX) announced entering into an agreement with a physician at the Mayo Clinic to perform additional research on Moleculin’s WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. Moleculin Biotech is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates.

 Mayo Clinic physician-scientists requested, and Moleculin Biotech Inc (NASDAQ:MBRX) agreed, to supply them with WP1066 for preclinical testing for the potential treatment of pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor.

Mayo Clinic studies have suggested that DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3, a primary target of WP1066, and their preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in vitro and in vivo tumor models.

In a statement, Moleculin Biotech Inc (NASDAQ:MBRX) Chairman and CEO, Walter Klemp, said they are thrilled to work with The Mayo Clinic in exploring the treatment potential of WP1066in in treating DIPG. He added that this should make it easier to secure an IND to study WP1066 for the treatment of adult brain tumors.

In other news, Moleculin Biotech Inc (NASDAQ:MBRX) has announced the discovery of a metabolic inhibitor with the potential to treat pancreatic cancer. Klemp announced that the company has received a lot of attention from the scientific and medical community following the company’s glucose decoy technology as a potential means of killing tumors by exploiting their hyper-dependence on glycolysis for energy production. He added that during the pre-clinical testing, the company’s WP1234 has shown improved drug characteristics compared to WP1122 and greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors of glycolysis. Klemp said that the discovery makes WP1234 a promising solution to kill pancreatic cancer which is known to survive in reduced oxygen environment.

According to Mr. Klemp, any small gain made in treating pancreatic cancer will make a significant gain in the medical field owing to the fact that the disease is largely regarded as untreatable. WP1234 works by improving on known inhibitors for glycolysis by increasing drug circulation time, which in turn increases the potential for drug uptake by destruction of tumor cells. Mr. Klemp said the discovery is a result of his company’s collaboration with M.D. Anderson Cancer Center.

During the Wednesday session, the stock of Moleculin Biotech Inc (NASDAQ:MBRX) reported a +17.31% or +$0.021 to close the session at $0.145.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Moleculin Biotech Inc (NASDAQ:MBRX) Shares Rocketing

Moleculin Biotech Inc (NASDAQ:MBRX)

Moleculin Biotech Inc (NASDAQ:MBRX) shares are rocketing higher by almost 30% after this morning’s announcement that the biotech company has discovered a metabolic inhibitor with the potential to treat pancreatic cancer. MBRX shares closed Tuesday at $0.85 and gapped up to open today at $1.14 before hitting an inter-day high of $1.30. At 11:10 AM EST MBRX shares are trading aournd $1.10. Volumes are extraordinarily heavy. Data suppliers list the 30-day, daily, average trading volume at around 717,000. However by 11 AM EST, over 11.4 million shares have exchanged hands.

Moleculin Biotech Inc (NASDAQ:MBRX) is a preclinical pharmaceutical company that develops anti-cancer drug candidates. Moleculin develops some of these drug candidates, utilizing license agreements, with The University of Texas System on behalf of the M.D. Anderson Cancer Center.

Walter Klemp, Chairman and CEO of Moleculin Biotech Inc (NASDAQ:MBRX) stated “In pre-clinical testing, WP1234 has shown improved drug characteristics when compared with WP1122 and a 20 to 50-fold greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors of glycolysis. We know that pancreatic cancer thrives even in a reduced oxygen environment, which indicates it may be highly dependent on glycolysis to survive. This discovery now makes WP1234 a promising drug candidate to be studied for the treatment of pancreatic cancer.”

The news is sure to be welcomed by beleaguered Moleculin shareholders. While MBRX shares are up 33% so far today, they are down over 62% YTD, and down over 86% for the year. Moleculin Biotech Inc (NASDAQ:MBRX) has never reported any sales and has three years of negative earnings, last year being the largest at (-$0.40). However the consensus target price amongst analysts covering MBRX is above $9.00.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.